Regulator: Sputnik V in Brazil different from Lancet study

sputnik v vaccine
Sputnik V vaccine. Photo: Gamaleya National Center of Epidemiology and Microbiology

A study published in medical journal The Lancet states that Russia’s Sputnik V vaccine has a 91.6-percent efficacy rate against the coronavirus. Brazilian federal regulators, however, says the data relates to a different vaccine from that which is attempting clearance for emergency use in Brazil. 

The agency says the results published in The Lancet relate to liquid vaccines stored at -18 degrees Celsius, while the Brazilian producers of Sputnik V propose different temperature and storage conditions.

União Química, the local producer of Sputnik V, has been called out by regulators for its slow pace in responding to information requests. The pharmaceutical group has yet to provide reports on late-stage clinical trial data proving efficacy rates of at least 50 percent.

Sputnik V in Latin America

The Mexican government has cleared the Russian vaccine for emergency use. It will be the third immunizer to be used in the country, following those by Pfizer and AstraZeneca. Hugo López Gatell, Mexico’s deputy health secretary, says 400,000 doses are expected to arrive “in a matter of days.”

Support this coverage →Support this coverage →